# Dogma Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dogma-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.dogmatherapeutics.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Apr 1, 2017)
- Investors on record: 2

## About

Based in Massachusetts, US, and established in 2017, Dogma Therapeutics is a biotechnology company that is developing oral small molecule drugs to treat high cholesterol and cardiovascular disease. The company founder is Doug Daniels. In April 2017, the company has raised USD 3.5 million in series A funding.

The company developed small molecule inhibitors of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), The function mutation of PCSK9 increased serum cholesterol and caused cardiovascular disease. Then, the company developed oral PCSK9 inhibitors for high cholesterol and cardiovascular disease. The oral PCSK9 inhibitors were developed, based on dozens of high-resolution x-ray structures of molecules bound, and structure-based design.

## Funding rounds

- Series A, Apr 1, 2017, $3.5M — Viva Ventures Biotech, Viva BioInnovator

## Investors

- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series A
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A